osimertinib
astrazeneca
[]
1 phase 2 (n=27) neoadjuvant osi (1-2 months) in egfr mutated (exon 19 del, l858r) surgically resectable egfr mutant tumors by 15%mpr
89% r0 resection rbm10 (common in l858r) in non-responders would longer duration of treatment improve outcome? #asco23 
MRCP(UK) •KBIM •Former Fellow @OttawaHospital •Thoracic and Sarcoma Medical Oncologist • Madridista 14/35 اختصاصي أول بالأمراض الباطنية وطب الأورام وأورام الرئة